600062 华润双鹤
已收盘 09-30 15:00:00
资讯
新帖
简况
股市必读：华润双鹤新发布《华润双鹤关于控股子公司华润双鹤湘中药业(湖南)有限公司布瑞哌唑原料药获得化学原料药上市申请批准通知书的公告》
证券之星 · 09-30 03:16
股市必读：华润双鹤新发布《华润双鹤关于控股子公司华润双鹤湘中药业(湖南)有限公司布瑞哌唑原料药获得化学原料药上市申请批准通知书的公告》
华润双鹤最新公告：子公司盐酸普萘洛尔注射液通过一致性评价
证券之星 · 09-23
华润双鹤最新公告：子公司盐酸普萘洛尔注射液通过一致性评价
华润双鹤最新公告：全资子公司依折麦布阿托伐他汀钙片获药品注册证书
证券之星 · 09-14
华润双鹤最新公告：全资子公司依折麦布阿托伐他汀钙片获药品注册证书
每周股票复盘：华润双鹤（600062）复方葡萄糖/电解质冲洗液获批
证券之星 · 09-13
每周股票复盘：华润双鹤（600062）复方葡萄糖/电解质冲洗液获批
华润双鹤（600062）披露复方葡萄糖/电解质颅脑手术冲洗液获得药品注册证书，9月9日股价上涨0.06%
证券之星 · 09-09
华润双鹤（600062）披露复方葡萄糖/电解质颅脑手术冲洗液获得药品注册证书，9月9日股价上涨0.06%
华润双鹤(600062.SH)：复方葡萄糖/电解质颅脑手术冲洗液获得药品注册证书
智通财经 · 09-08
华润双鹤(600062.SH)：复方葡萄糖/电解质颅脑手术冲洗液获得药品注册证书
每周股票复盘：华润双鹤（600062）奥卡西平片获注册证书
证券之星 · 09-06
每周股票复盘：华润双鹤（600062）奥卡西平片获注册证书
股市必读：华润双鹤新发布《华润双鹤关于洛莫司汀胶囊获得药品注册证书的公告》
证券之星 · 09-03
股市必读：华润双鹤新发布《华润双鹤关于洛莫司汀胶囊获得药品注册证书的公告》
华润双鹤（600062）披露洛莫司汀胶囊获得药品注册证书公告，9月1日股价上涨0.06%
证券之星 · 09-01
华润双鹤（600062）披露洛莫司汀胶囊获得药品注册证书公告，9月1日股价上涨0.06%
华润双鹤(600062.SH)子公司奥卡西平片获得药品注册证书
智通财经 · 08-31
华润双鹤(600062.SH)子公司奥卡西平片获得药品注册证书
华润双鹤：积极研究运用股份回购、大股东增持、股权激励等市值管理工具
证券之星 · 08-31
华润双鹤：积极研究运用股份回购、大股东增持、股权激励等市值管理工具
股市必读：华润双鹤新发布《华润双鹤关于重大资产重组的进展公告》
证券之星 · 08-31
股市必读：华润双鹤新发布《华润双鹤关于重大资产重组的进展公告》
每周股票复盘：华润双鹤（600062）拟购利尔化学23.50%股份
证券之星 · 08-30
每周股票复盘：华润双鹤（600062）拟购利尔化学23.50%股份
利尔化学（002258）披露控股股东及持股5%以上股东拟向华润双鹤转让合计23.50%股份，8月27日股价上涨0.64%
证券之星 · 08-27
利尔化学（002258）披露控股股东及持股5%以上股东拟向华润双鹤转让合计23.50%股份，8月27日股价上涨0.64%
华润双鹤董事长陆文超：打造合成生物第二增长曲线
中国财富通 · 08-24
华润双鹤董事长陆文超：打造合成生物第二增长曲线
每周股票复盘：华润双鹤（600062）上半年营收净利双降
证券之星 · 08-23
每周股票复盘：华润双鹤（600062）上半年营收净利双降
图解华润双鹤中报：第二季度单季净利润同比下降2.49%
证券之星 · 08-22
图解华润双鹤中报：第二季度单季净利润同比下降2.49%
华润双鹤（600062）披露2026年半年度报告，8月21日股价下跌3.33%
证券之星 · 08-21
华润双鹤（600062）披露2026年半年度报告，8月21日股价下跌3.33%
股市必读：华润双鹤新发布《华润双鹤关于盐酸利多卡因凝胶获得药品注册证书的公告》
证券之星 · 08-20
股市必读：华润双鹤新发布《华润双鹤关于盐酸利多卡因凝胶获得药品注册证书的公告》
华润双鹤（600062）披露2021年限制性股票激励计划回购注销实施公告，8月18日股价下跌0.56%
证券之星 · 08-18
华润双鹤（600062）披露2021年限制性股票激励计划回购注销实施公告，8月18日股价下跌0.56%
加载更多
公司概况
公司名称：
华润双鹤药业股份有限公司
所属行业：
医药制造业
上市日期：
1997-05-22
主营业务：
华润双鹤药业股份有限公司的主营业务是慢病业务、专科业务、输液业务。公司的主要产品是缬沙坦、氨氯地平、普瑞巴林、氨苯蝶啶、喷他佐辛、匹伐他汀、肝素钠、依诺肝素原料。
发行价格：
6.69
{"stockData":{"symbol":"600062","market":"SH","secType":"STK","nameCN":"华润双鹤","latestPrice":16.24,"timestamp":1790751600000,"preClose":15.92,"halted":0,"volume":8632253,"delay":0,"changeRate":0.0201,"floatShares":1038000000,"shares":1039000000,"eps":1.5577,"marketStatus":"已收盘","change":0.32,"latestTime":"09-30 15:00:00","open":15.97,"high":16.28,"low":15.91,"amount":140000000,"amplitude":0.0232,"askPrice":16.25,"askSize":110,"bidPrice":16.24,"bidSize":98,"shortable":0,"etf":0,"ttmEps":1.5577,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"adjPreClose":15.92,"symbolType":"stock","openAndCloseTimeList":[[1790731800000,1790739000000],[1790744400000,1790751600000]],"highLimit":17.51,"lowLimit":14.33,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1038572452,"isCdr":false,"pbRate":1.38,"roa":"--","peRate":10.425628,"roe":"7.68%","epsLYR":1.5949,"committee":-0.761718,"marketValue":16866000000,"turnoverRate":0.0083,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-10-08。","floatMarketCap":16861000000},"requestUrl":"/m/hq/s/600062","defaultTab":"news","newsList":[{"id":"2671265244","title":"股市必读：华润双鹤新发布《华润双鹤关于控股子公司华润双鹤湘中药业(湖南)有限公司布瑞哌唑原料药获得化学原料药上市申请批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2671265244","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671265244?lang=zh_cn&edition=full","pubTime":"2026-09-30 03:16","pubTimestamp":1790709374,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘，华润双鹤报收于15.92元，下跌0.38%，换手率0.37%，成交量3.8万手，成交额6053.05万元。当日关注点交易信息汇总：9月29日游资资金净流入610.85万元，占总成交额10.09%，为当日主力资金流向中最显著项。公司公告汇总：控股子公司华润双鹤湘中药业布瑞哌唑原料药获国家药监局批准注册，适用于治疗成人精神分裂症，累计研发投入969.87万元。双鹤湘中于2025年3月7日提交申请，2026年9月21日获批，在CDE原辅包登记平台状态为“A”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000002986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062","BK0010","BK0175","BK0239","BK0028","BK0185","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669104682","title":"华润双鹤最新公告：子公司盐酸普萘洛尔注射液通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2669104682","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669104682?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:29","pubTimestamp":1790155742,"startTime":"0","endTime":"0","summary":"华润双鹤(600062.SH)公告称，公司全资子公司华润紫竹药业收到国家药监局颁发的盐酸普萘洛尔注射液《药品补充申请批准通知书》，批准增加2ml:2mg规格，该药品通过仿制药质量和疗效一致性评价。该药品适用于控制室上性快速心律失常、劳力型心绞痛等。截至公告日，公司累计研发投入333.84万元。2025年该药品销售收入306.22万元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300029726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062","BK0010","BK0185","BK0239","BK0175","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654139","title":"华润双鹤最新公告：全资子公司依折麦布阿托伐他汀钙片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654139","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667654139?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:27","pubTimestamp":1789378071,"startTime":"0","endTime":"0","summary":"华润双鹤(600062.SH)公告称，公司全资子公司华润赛科收到国家药监局颁发的依折麦布阿托伐他汀钙片(含Ⅰ、Ⅱ两种规格)《药品注册证书》，视同通过一致性评价。该药品适用于高胆固醇血症和纯合子型家族性高胆固醇血症的治疗。截至公告日，公司累计研发投入2036.37万元。本次获批将进一步丰富公司产品线，提升市场竞争力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400022576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","600062","BK0188","BK0010","BK0175","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667070425","title":"每周股票复盘：华润双鹤（600062）复方葡萄糖/电解质冲洗液获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2667070425","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667070425?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:55","pubTimestamp":1789239309,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，华润双鹤报收于15.83元，较上周的16.02元下跌1.19%。本周，华润双鹤9月9日盘中最高价报16.31元。华润双鹤当前最新总市值164.41亿元，在化学制药板块市值排名26/149，在两市A股市值排名1151/5218。公司于2023年6月启动研发，2024年12月提交上市申请，2026年9月获批，累计研发投入1,324.62万元。该产品视同通过一致性评价。目前国内已有4家企业获批，2025年国内市场规模为6万元。该药品上市将丰富公司产品线，提升市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0239","BK0188","BK0185","BK0028","600062","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666581125","title":"华润双鹤（600062）披露复方葡萄糖/电解质颅脑手术冲洗液获得药品注册证书，9月9日股价上涨0.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666581125","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666581125?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:38","pubTimestamp":1788946738,"startTime":"0","endTime":"0","summary":"截至2026年9月9日收盘，华润双鹤报收于16.21元，较前一交易日上涨0.06%，最新总市值为168.35亿元。该股当日开盘16.21元，最高16.31元，最低16.09元，成交额达7379.88万元，换手率为0.44%。华润双鹤药业股份有限公司近日收到国家药品监督管理局颁发的复方葡萄糖/电解质颅脑手术冲洗液《药品注册证书》，该药品为化学药品3类，适用于颅脑手术、脊髓疾病手术及神经内镜手术时的洗净与灌流。该药品上市将丰富公司产品线，提升市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900030214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0028","BK0185","600062","BK0188","BK0239","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326372","title":"华润双鹤(600062.SH)：复方葡萄糖/电解质颅脑手术冲洗液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326372","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665326372?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:06","pubTimestamp":1788858414,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司收到了国家药品监督管理局颁发的复方葡萄糖/电解质颅脑手术冲洗液《药品注册证书》。该药品适用于颅骨钻孔、开颅手术时的洗净、脊髓疾病手术时的洗净及神经内镜手术时的灌流。此次获得《药品注册证书》视同通过一致性评价。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)：复方葡萄糖/电解质颅脑手术冲洗液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0175","BK0239","BK0010","BK0185","BK0188","600062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665366853","title":"每周股票复盘：华润双鹤（600062）奥卡西平片获注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2665366853","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665366853?lang=zh_cn&edition=full","pubTime":"2026-09-06 02:54","pubTimestamp":1788634452,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，华润双鹤报收于16.02元，较上周的16.16元下跌0.87%。公司公告汇总华润双鹤控股子公司华润双鹤湘中药业(湖南)有限公司近日收到国家药监局颁发的奥卡西平片《药品注册证书》，视同通过一致性评价。华润双鹤药业股份有限公司近日获得国家药监局颁发的洛莫司汀胶囊《药品注册证书》，该药品为化学药品5.1类，规格为40mg，适用于经手术和/或放疗后的原发性恶性脑肿瘤患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0188","BK0185","BK0028","BK0175","BK0239","600062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664845165","title":"股市必读：华润双鹤新发布《华润双鹤关于洛莫司汀胶囊获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664845165","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664845165?lang=zh_cn&edition=full","pubTime":"2026-09-03 02:10","pubTimestamp":1788372623,"startTime":"0","endTime":"0","summary":"公司公告汇总：华润双鹤获得洛莫司汀胶囊《药品注册证书》，为化学药品5.1类，规格40mg，获批时间2026年8月25日，获6年数据保护期。公司公告汇总华润双鹤关于洛莫司汀胶囊获得药品注册证书的公告华润双鹤药业股份有限公司近日获得国家药监局颁发的洛莫司汀胶囊《药品注册证书》，该药品为化学药品5.1类，规格为40mg，适用于经手术和/或放疗后的原发性恶性脑肿瘤患者。截至公告日，累计研发投入222.98万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300001968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0185","BK0010","600062","BK0239","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664857025","title":"华润双鹤（600062）披露洛莫司汀胶囊获得药品注册证书公告，9月1日股价上涨0.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664857025","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664857025?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:57","pubTimestamp":1788274631,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘，华润双鹤报收于16.09元，较前一交易日上涨0.06%，最新总市值为167.11亿元。该股当日开盘16.02元，最高16.14元，最低15.97元，成交额达9819.78万元，换手率为0.59%。华润双鹤近日发布关于洛莫司汀胶囊获得药品注册证书的公告。公告显示，公司近日获得国家药监局颁发的洛莫司汀胶囊《药品注册证书》，该药品为化学药品5.1类，规格为40mg，适用于经手术和/或放疗后的原发性恶性脑肿瘤患者。截至公告日，累计研发投入222.98万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100043440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0175","BK0185","BK0239","BK0028","600062","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663076587","title":"华润双鹤(600062.SH)子公司奥卡西平片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2663076587","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663076587?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:02","pubTimestamp":1788166955,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司控股子公司华润双鹤湘中药业(湖南)有限公司收到了国家药品监督管理局颁发的奥卡西平片《药品注册证书》。奥卡西平片适用于治疗成年人和5岁及以上儿童的原发性全面性强直-阵挛发作和部分性发作，伴有或不伴有继发性全面性发作。此次获得《药品注册证书》视同通过一致性评价。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0010","BK0028","BK0175","BK0185","600062","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663078741","title":"华润双鹤：积极研究运用股份回购、大股东增持、股权激励等市值管理工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2663078741","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663078741?lang=zh_cn&edition=full","pubTime":"2026-08-31 15:36","pubTimestamp":1788161810,"startTime":"0","endTime":"0","summary":"证券之星消息，华润双鹤(600062)08月31日在投资者关系平台上答复投资者关心的问题。投资者提问：资金在哪里？股票跌跌不休华润双鹤回复：感谢您对公司的关注！二级市场股价受宏观环境、行业政策、资金偏好等多重因素综合影响，具有不确定性。公司将结合财务状况、发展战略等综合因素，积极研究运用股份回购、大股东增持、股权激励等市值管理工具，促进公司整体市值实现持续、健康提升。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100015876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","600062","BK0175","BK0185","BK0010","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663047024","title":"股市必读：华润双鹤新发布《华润双鹤关于重大资产重组的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2663047024","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663047024?lang=zh_cn&edition=full","pubTime":"2026-08-31 06:26","pubTimestamp":1788128771,"startTime":"0","endTime":"0","summary":"公司公告汇总：华润双鹤拟以现金方式收购利尔化学23.50%股份，构成重大资产重组，目前正推进尽职调查、审计及评估工作。公司公告汇总华润双鹤关于重大资产重组的进展公告华润双鹤药业股份有限公司拟以支付现金方式购买四川久远投资控股集团有限公司、四川化材科技有限公司合计持有的利尔化学股份有限公司188,102,749股股份，占其总股本的23.50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100001611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0239","BK0185","BK0188","600062","BK0028","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663001000","title":"每周股票复盘：华润双鹤（600062）拟购利尔化学23.50%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2663001000","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663001000?lang=zh_cn&edition=full","pubTime":"2026-08-30 04:50","pubTimestamp":1788036618,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，华润双鹤报收于16.16元，较上周的15.67元上涨3.13%。本周，华润双鹤8月26日盘中最高价报16.33元。本周关注点公司公告汇总：华润双鹤拟以支付现金方式购买利尔化学23.50%股份，交易完成后控股股东将变更为华润双鹤。公司公告汇总华润双鹤药业股份有限公司拟以支付现金方式购买四川久远投资控股集团有限公司、四川化材科技有限公司合计持有的利尔化学股份有限公司188,102,749股股份，占其总股本的23.50%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0229","002258","BK0186","BK0122","BK0201","BK0010","600062","BK0028","BK0239","BK0175","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085327","title":"利尔化学（002258）披露控股股东及持股5%以上股东拟向华润双鹤转让合计23.50%股份，8月27日股价上涨0.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085327","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662085327?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:06","pubTimestamp":1787839598,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，利尔化学报收于14.16元，较前一交易日上涨0.64%，最新总市值为113.34亿元。近日，利尔化学披露公告显示，公司控股股东四川久远投资控股集团有限公司、持股5%以上股东四川化材科技有限公司拟通过公开征集转让方式分别转让其所持公司部分股份，合计向华润双鹤转让188,102,749股股份，占公司总股本的23.50%，转让价格为30.07元/股，转让总价5,656,249,662.43元。本次权益变动后，华润双鹤预计将成公司控股股东，中国华润有限公司将成为公司实际控制人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700054566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","BK0028","BK0201","BK0175","BK0239","BK0010","BK0122","002258","BK0186","BK0185","BK0188","600062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662300587","title":"华润双鹤董事长陆文超：打造合成生物第二增长曲线","url":"https://stock-news.laohu8.com/highlight/detail?id=2662300587","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662300587?lang=zh_cn&edition=full","pubTime":"2026-08-24 15:21","pubTimestamp":1787556085,"startTime":"0","endTime":"0","summary":"近日，华润双鹤董事长陆文超做客《直面掌门人》，详解交易背后的战略逻辑。华润双鹤董事长陆文超战略起点：从技术积累到产业破局“合成生物技术是当前全球科技竞争的前沿领域，也是国家战略性未来产业的重点方向。”华润双鹤历经五年积淀，创新药领域已布局15个产品管线，合成生物领域储备20余个品种。在陆文超看来，第一曲线与第二曲线并非此消彼长，而是相互促进。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=o5U56AdCI3w%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0239","BK0175","600062","BK0010","BK0185","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661211145","title":"每周股票复盘：华润双鹤（600062）上半年营收净利双降","url":"https://stock-news.laohu8.com/highlight/detail?id=2661211145","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661211145?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:06","pubTimestamp":1787421973,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，华润双鹤报收于15.67元，较上周的16.0元下跌2.06%。本周，华润双鹤8月20日盘中最高价报16.29元。股本股东变化股东户数变动截至2026年6月30日，华润双鹤股东户数为5.27万户，较3月31日减少2236.0户，减幅为4.07%。业绩披露要点财务报告华润双鹤2026年中报显示，上半年主营收入56.15亿元，同比下降3.44%；归母净利润9.46亿元，同比下降3.43%；扣非净利润9.02亿元，同比下降3.27%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661294960","title":"图解华润双鹤中报：第二季度单季净利润同比下降2.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661294960","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661294960?lang=zh_cn&edition=full","pubTime":"2026-08-22 01:17","pubTimestamp":1787332662,"startTime":"0","endTime":"0","summary":"证券之星消息，华润双鹤2026年中报显示，上半年度公司主营收入56.15亿元，同比下降3.44%；归母净利润9.46亿元，同比下降3.43%；扣非净利润9.02亿元，同比下降3.27%；其中2026年第二季度，公司单季度主营收入28.09亿元，同比上升2.64%；单季度归母净利润4.61亿元，同比下降2.49%；单季度扣非净利润4.33亿元，同比下降3.01%；负债率28.45%，投资收益9183.93万元，财务费用2033.41万元，毛利率58.11%。财报数据概要请见下图:本文数据来源于华润双鹤2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200001684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661296885","title":"华润双鹤（600062）披露2026年半年度报告，8月21日股价下跌3.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661296885","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661296885?lang=zh_cn&edition=full","pubTime":"2026-08-21 22:08","pubTimestamp":1787321302,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，华润双鹤报收于15.67元，较前一交易日下跌3.33%，最新总市值为162.74亿元。近日，华润双鹤药业股份有限公司披露2026年半年度报告。公司拟以实施权益分派股权登记日登记的总股本为基数，向全体股东每10股派发现金红利1.00元（含税）。截至2026年6月30日，公司总股本为1,038,582,511股，扣除已回购注销的10,059股后，合计拟派发现金红利103,857,245.20元（含税）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100045139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0175","600062","BK0010","BK0185","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660205924","title":"股市必读：华润双鹤新发布《华润双鹤关于盐酸利多卡因凝胶获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660205924","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660205924?lang=zh_cn&edition=full","pubTime":"2026-08-20 02:27","pubTimestamp":1787164030,"startTime":"0","endTime":"0","summary":"公司公告汇总华润双鹤关于盐酸利多卡因凝胶获得药品注册证书的公告华润双鹤药业股份有限公司收到国家药品监督管理局颁发的盐酸利多卡因凝胶《药品注册证书》，规格为2%，注册分类为化学药品3类，视同通过一致性评价。2025年国内盐酸利多卡因凝胶市场销售总额为1.25亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000002276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0185","BK0239","BK0175","600062","BK0010","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660493828","title":"华润双鹤（600062）披露2021年限制性股票激励计划回购注销实施公告，8月18日股价下跌0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660493828","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660493828?lang=zh_cn&edition=full","pubTime":"2026-08-18 22:18","pubTimestamp":1787062705,"startTime":"0","endTime":"0","summary":"截至2026年8月18日收盘，华润双鹤报收于15.97元，较前一交易日下跌0.56%，最新总市值为165.86亿元。该股当日开盘16.0元，最高16.13元，最低15.89元，成交额达1.11亿元，换手率为0.67%。近日，华润双鹤发布《关于2021年限制性股票激励计划回购注销实施公告》。本次回购注销已于2026年3月18日经第十届董事会第十八次会议审议通过，并履行了相关信息披露及债权人通知程序。回购股份已于2026年8月21日完成注销，公司总股本相应减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800042487.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0028","BK0188","600062","BK0239","BK0010","BK0185"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790812635482,"stockEarnings":[{"period":"1week","weight":0.0131},{"period":"1month","weight":0.01},{"period":"3month","weight":-0.0081},{"period":"6month","weight":-0.1053},{"period":"1year","weight":-0.1059},{"period":"ytd","weight":-0.0916}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润双鹤药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"52736人(较上一季度减少4.07%)","perCapita":"19687股","listingDate":"1997-05-22","address":"北京市朝阳区望京利泽东二路1号","registeredCapital":"103857万元","survey":" 华润双鹤药业股份有限公司的主营业务是慢病业务、专科业务、输液业务。公司的主要产品是缬沙坦、氨氯地平、普瑞巴林、氨苯蝶啶、喷他佐辛、匹伐他汀、肝素钠、依诺肝素原料。","listedPrice":6.69},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华润双鹤,600062,华润双鹤股票,华润双鹤股票老虎,华润双鹤股票老虎国际,华润双鹤行情,华润双鹤股票行情,华润双鹤股价,华润双鹤股市,华润双鹤股票价格,华润双鹤股票交易,华润双鹤股票购买,华润双鹤股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}